Ruserontinib (SKLB1028) (5-70 mg/kg, orally once daily, 18 days) have anti-tumor effect in MV4-11 and K562 xenograft NOD-SCID models[1].
| Animal Model: | MV4-11 and K562 xenograft NOD-SCID models[1] |
| Dosage: | 5, 10, 20 mg/kg,70 mg/kg |
| Administration: | orally once daily, 18 days |
| Result: | Prevented tumor growth at a dose of 5 mg/kg, and caused rapid and complete tumor regression in both groups of mice at a dose of 10 or 20 mg/kg.
Significantly inhibited the proliferation and induced apoptosis of MV4-11 and K562 cells at a dose of 70 mg/kg. |
